Market Assessment, Market Events and Forecast Endocrinology US/EU5 2021 Report

In 2019, sales of insulins at the ex-manufacturer price level exceeded $11 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, the originator insulins manufactured by Eli Lilly, Novo Nordisk, and Sanofi will face increasing competition from insulin biosimilars / follow-on insulins, eroding both patient share and drug prices. We present our forecasts for key reference brand insulins and their biosimilars / follow-on insulins by therapeutic area, molecule, and country / region.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Market Events and Forecast | Endocrinology | US/EU5 | 2021

Related Market Assessment Reports

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Urticaria – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Chronic Inducible Urticaria (US) 2023

Ulcerative Colitis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Adult (US)

Asthma | Unmet Need | Severe Asthma | US/EU | 2021

Asthma – Unmet Need – Detailed, Expanded Analysis – Severe Asthma (US/EU)